Does SummaCare Cover Eliquis? A Woman's Complete Guide to Apixaban Coverage, Cost, and Safety

Does SummaCare Actually Cover Eliquis?

SummaCare covers Eliquis on the majority of its formularies, but the coverage level, tier placement, and required steps vary by plan type. Eliquis is not a generic drug, and that single fact drives most of the frustration women report at the pharmacy counter.

SummaCare is a regional health plan headquartered in Akron, Ohio, offering Medicare Advantage, Medicare Supplement, and employer-group commercial plans. Because each plan maintains its own formulary, the answer "yes, it's covered" can still mean you owe hundreds of dollars per fill if your plan places apixaban on Tier 3 (preferred brand) or Tier 4 (non-preferred brand).

Why Tier Placement Matters So Much

Most SummaCare Medicare Advantage plans use a five-tier formulary structure. Tier 1 drugs (generics) carry the lowest copays, often $0 to $10. Tier 3 or Tier 4 placement for Eliquis typically means:

• A fixed copay of $40 to $100 per 30-day supply during the initial coverage phase
• Much higher costs once you enter the Medicare Part D coverage gap ("donut hole"), where you pay 25 percent of the drug's list price
• Potential catastrophic-phase relief once your true out-of-pocket spending crosses the annual threshold ($8,000 in 2025 under the Inflation Reduction Act)

For commercial SummaCare members, the tier structure differs but the principle is the same: the higher the tier, the higher your share of cost.

Prior Authorization: The Step Most Women Don't Expect

SummaCare requires prior authorization (PA) for Eliquis on many of its plans. That means your prescriber must submit documentation showing the medical necessity of apixaban specifically, rather than a less expensive alternative such as warfarin. Common approved indications include:

• Non-valvular atrial fibrillation (AF) with stroke prevention
• Deep vein thrombosis (DVT) treatment or prevention
• Pulmonary embolism (PE) treatment
• Post-surgical thromboprophylaxis (hip or knee replacement)

If your PA is denied, your prescriber can file an appeal or request a formulary exception. This process takes anywhere from 72 hours to two weeks, depending on urgency and plan policy.

How to Check Your Specific SummaCare Plan Coverage

The single most reliable step is to look up Eliquis (apixaban, NDC or drug name) in SummaCare's online formulary search tool at SummaCare's member portal. The formulary is updated quarterly, and a drug's tier can change mid-year.

You can also call the Member Services number on the back of your SummaCare insurance card and ask these four specific questions:

1. Is apixaban (brand name Eliquis) on my formulary?
2. What tier is it listed on?
3. Is prior authorization required?
4. What is my copay during the initial coverage phase, in the coverage gap, and after catastrophic threshold?

Your pharmacist can also run a real-time benefits check before you pick up your prescription, which shows your actual out-of-pocket cost given your current deductible accumulation.

Women, Blood Clots, and Why Eliquis Gets Prescribed

Eliquis is a direct oral anticoagulant (DOAC) that works by inhibiting Factor Xa, a key step in the clotting cascade. The ARISTOTLE trial (2011) showed apixaban reduced stroke or systemic embolism by 21 percent compared with warfarin in patients with atrial fibrillation, with significantly less major bleeding. That trial enrolled women, though they made up only 35 percent of participants, a point addressed in more detail below.

Conditions That Increase Clot Risk in Women

Women face several clot-risk factors that men do not:

• Oral contraceptives and hormonal IUDs. Combined estrogen-progestin pills raise venous thromboembolism (VTE) risk 2 to 4 times above baseline. If you are on both a combined pill and an anticoagulant for another reason, your prescriber should reassess contraceptive method.
• Menopausal hormone therapy (MHT). Oral estrogen raises clot risk; transdermal estrogen does not carry the same degree of first-pass hepatic effect and appears to carry lower VTE risk than oral forms, as supported by the ESTHER study.
• PCOS. Polycystic ovary syndrome is associated with insulin resistance, elevated androgens, and a prothrombotic coagulation profile. Women with PCOS who also smoke or carry excess visceral adiposity may have a compounded clot risk, though direct apixaban trial data in PCOS women is limited (see evidence gap section below).
• Pregnancy. Pregnancy itself increases clot risk 5-fold due to venous stasis, hypercoagulability, and vessel wall changes. However, Eliquis is not the solution: it is contraindicated in pregnancy (see dedicated section).
• Antiphospholipid syndrome (APS). APS, which disproportionately affects women, is a notable exception where DOACs like apixaban are generally avoided in favor of warfarin. The TRAPS trial found rivaroxaban inferior to warfarin in high-risk APS patients, and current guidance extends similar caution to all DOACs in triple-positive APS.
• Atrial fibrillation. AF is increasingly recognized as underdiagnosed in women. Women with AF have a higher absolute stroke risk than men at equivalent CHA₂DS₂-VASc scores, which often justifies anticoagulation at lower score thresholds.

Sex-Specific Pharmacology of Apixaban

Women metabolize apixaban differently than men, and that is not a footnote. It has clinical consequences.

Pharmacokinetics in Women

Apixaban is primarily metabolized via CYP3A4 with additional renal clearance. Body weight, renal function, and age all influence drug exposure. Women, on average, have lower body weight than men, and lower weight is associated with higher plasma drug concentrations per dose. The apixaban prescribing information identifies weight <60 kg as one of three criteria used to determine dose reduction (the others are age ≥80 and creatinine ≥1.5 mg/dL). If you meet two of those three criteria, the dose for AF drops from 5 mg twice daily to 2.5 mg twice daily.

Women are more likely than men to meet the low-weight criterion, meaning dose reduction is more commonly indicated in women. A provider who does not screen for these criteria before prescribing may give a woman the standard dose when a lower dose is clinically correct.

Bleeding Risk Differences

Major bleeding is the central safety concern with any anticoagulant. In ARISTOTLE, women had lower absolute rates of major bleeding than men, but they were also more likely to experience nuisance bleeding such as heavy menstrual bleeding (HMB). Apixaban and other DOACs are associated with increased menstrual blood loss, which can progress to iron deficiency anemia in women who are already menstruating heavily due to fibroids, adenomyosis, or other structural causes.

If you are on Eliquis and your periods have become significantly heavier or longer, that change deserves clinical attention. It is not simply a side effect to tolerate. Options include adjusting the anticoagulant, adding tranexamic acid during menses (with prescriber approval), or addressing underlying uterine pathology.

Renal Function Across the Life Span

Renal function declines with age, and since apixaban is partially renally cleared, older postmenopausal women are more likely to require dose reduction or closer monitoring. Creatinine-based eGFR estimates can overestimate true renal clearance in older women who have less muscle mass, since creatinine is a muscle breakdown product. Cystatin C-based eGFR may be a more accurate marker in thin, older women.

Pregnancy, Lactation, and Contraception

Eliquis is contraindicated in pregnancy. This is not a soft recommendation. Apixaban crosses the placenta. Animal reproduction studies have shown fetal toxicity at clinically relevant doses. Human data in pregnancy is essentially absent for efficacy and safety, and the FDA label explicitly states that apixaban is not recommended during pregnancy due to the risk of fetal hemorrhage and maternal bleeding complications during delivery.

What to Use Instead

For pregnant women who require anticoagulation, the standard of care is low-molecular-weight heparin (LMWH), most commonly enoxaparin (Lovenox). ACOG Practice Bulletin No. 196 on thromboembolism in pregnancy recommends LMWH as first-line therapy because it does not cross the placenta and does not carry fetal bleeding risk. Warfarin carries teratogenic risk in the first trimester and is also avoided in most cases.

If you are of reproductive age and prescribed Eliquis for AF or VTE, you and your prescriber need an explicit contraception conversation. Reliable contraception is required. Because combined estrogen-progestin pills raise clot risk, a progestin-only method (progestin-only pill, hormonal IUD, or implant) or a barrier method may be more appropriate.

Lactation

Human data on apixaban transfer into breast milk is absent. Animal studies show transfer does occur. Because the potential for bleeding in a nursing infant cannot be excluded, the FDA label advises against breastfeeding while taking apixaban. If anticoagulation is medically necessary in the postpartum period and a woman wishes to breastfeed, LMWH is generally preferred because it does not transfer significantly into breast milk at therapeutic doses.

The Evidence Gap for Women

Women have been systematically underrepresented in cardiovascular drug trials, and the DOAC trials are no exception. ARISTOTLE enrolled only 35 percent women. AMPLIFY, the landmark apixaban trial for VTE treatment, enrolled approximately 40 percent women. Neither trial was powered to detect sex-specific differences in bleeding outcomes or drug exposure with statistical confidence.

What this means for you practically:

• Dose-reduction thresholds, bleeding risk estimates, and stroke-prevention efficacy data are primarily derived from populations where men predominate.
• Sex-disaggregated subgroup analyses exist but are underpowered.
• Data in pregnancy, the postpartum period, and women with hormone-driven conditions (PCOS, endometriosis, those on MHT) are extrapolated from general adult data or preclinical models, not direct human trials.

When your prescriber presents Eliquis as "proven effective," that is accurate at a population level. The honest qualifier is that the precision of that evidence in a woman your age, with your hormonal status, is lower than the headline trial results suggest. Insisting on sex-disaggregated data or asking your prescriber what the female-specific bleeding risk was in ARISTOTLE is a clinically reasonable question.

Who This Is Right For (and Who Should Think Twice)

Life Stages Where Eliquis May Be Appropriate

Postmenopausal women with AF. Postmenopausal women carry higher absolute stroke risk than premenopausal women at the same CHA₂DS₂-VASc score. Eliquis is a reasonable first-line choice in this group, provided renal function and weight-based dose adjustments are applied correctly. If you are also on systemic MHT, your prescriber should document that the combined thrombotic-plus-anticoagulant picture has been assessed.

Women with VTE not related to APS. For DVT or PE unrelated to antiphospholipid syndrome, apixaban is a guideline-recommended option. The AMPLIFY trial showed apixaban was non-inferior to warfarin for VTE treatment and caused 69 percent less major bleeding, a clinically meaningful reduction.

Perimenopausal women with new-onset AF. AF incidence rises in perimenopause partly due to estrogen fluctuation affecting cardiac ion channels. If you receive a new AF diagnosis during perimenopause, anticoagulation decisions should be made in the context of your CHA₂DS₂-VASc score and your MHT plans.

When to Think Carefully or Choose an Alternative

• Triple-positive antiphospholipid syndrome. Warfarin remains preferred; DOACs, including apixaban, should be avoided.
• Valvular AF (mechanical heart valves or moderate-to-severe mitral stenosis). Warfarin is still the only approved anticoagulant; Eliquis is not indicated.
• Severe renal impairment (CrCl <25 mL/min). Limited trial data; warfarin may be safer, though the decision is individualized.
• Active pregnancy or planned pregnancy within the next cycle. Switch to LMWH before conception if anticoagulation is still required.
• Women with heavy menstrual bleeding at baseline. Eliquis may worsen HMB substantially. A tranexamic acid plan or a hormonal IUD (to reduce menstrual flow) should be part of the conversation before starting.

Lowering Your Out-of-Pocket Cost on SummaCare

Manufacturer Assistance Programs

Bristol-Myers Squibb and Pfizer co-market Eliquis and offer the Eliquis 360 Support program. For commercially insured patients who qualify, the copay card can reduce monthly cost to as low as $10. Medicare beneficiaries are not eligible for manufacturer copay cards under federal law, but SummaCare Medicare Advantage members may qualify for the Extra Help (Low Income Subsidy) program, which can significantly reduce Part D drug costs.

Step Therapy and Formulary Exceptions

Some SummaCare plans require step therapy, meaning you must first try warfarin and demonstrate a clinical reason to escalate to Eliquis. Your prescriber can often bypass step therapy by documenting:

• INR instability on warfarin
• Drug or food interactions that make warfarin management difficult
• Patient preference supported by clinical rationale
• A condition (like prior warfarin-related bleeding) that makes warfarin higher risk

A formulary exception request, filed by your prescriber directly to SummaCare's pharmacy benefits department, can also move Eliquis to a lower cost-sharing tier for your specific case.

The $35 Insulin Rule Does Not Apply to Eliquis

The Inflation Reduction Act capped insulin at $35/month for Medicare Part D beneficiaries. That cap does not extend to other drugs including Eliquis. Some women confuse this benefit. Eliquis costs are governed by your plan's standard tier structure until you reach the catastrophic spending threshold.

90-Day Supply vs. 30-Day Fills

Ordering a 90-day supply through SummaCare's preferred mail-order pharmacy often reduces per-unit cost and reduces the number of copays you pay per year. Ask your prescriber to send a 90-day prescription if your dose is stable.

Eliquis and Conditions Common in Women

Atrial Fibrillation and Hormonal Status

Estrogen has electrophysiological effects on cardiac tissue. Fluctuating estrogen during perimenopause may increase arrhythmia vulnerability. Hot flashes and sleep disruption in perimenopause compound sympathetic nervous system activation, which can trigger AF episodes. If your AF is new and you are in perimenopause, addressing the menopause transition with appropriate MHT (transdermal, given its lower VTE risk) may reduce AF burden while Eliquis manages stroke risk.

PCOS and Thromboembolism

PCOS affects an estimated 6 to 12 percent of reproductive-age women in the United States. The condition's prothrombotic profile, driven by hyperinsulinemia, elevated androgen levels, and chronic low-grade inflammation, can compound VTE risk, particularly in women who use combined oral contraceptives to manage PCOS symptoms. If you have PCOS, a history of VTE, and need contraception, the combined pill may not be the right choice. A progestin-only pill or a copper or hormonal IUD avoids the additional estrogen-related clot risk.

Endometriosis and Fibroids

These conditions do not directly require anticoagulation, but they do cause heavy menstrual bleeding that apixaban can worsen significantly. A woman prescribed Eliquis who has known fibroids or endometriosis should have a baseline assessment of menstrual blood loss before starting therapy, and a plan ready if HMB escalates.

Monitoring and Practical Management

Unlike warfarin, apixaban does not require routine INR monitoring. That is a genuine convenience advantage. But "no routine monitoring" does not mean "no follow-up at all."

Specific monitoring steps for women on Eliquis:

• Annual renal function check. As creatinine rises, drug clearance falls and dose reduction may become necessary.
• Menstrual bleeding diary. Track pad or tampon use per day and note any clots larger than a quarter. Bring this log to each prescriber visit.
• Hemoglobin and ferritin annually. Women on anticoagulants who menstruate are at real risk of iron deficiency anemia. A ferritin below 30 ng/mL warrants iron supplementation.
• Medication reconciliation at every visit. CYP3A4 inducers (rifampin, St. John's wort, carbamazepine) can reduce apixaban levels by up to 50 percent. CYP3A4 inhibitors (ketoconazole, clarithromycin, some HIV antiretrovirals) can raise levels. Some women take herbal supplements or over-the-counter products that interact without realizing it.